NET PROFIT (x1000 DKK)
EMPLOYEES
Asarina Pharma AB (publ)
Closing information (x1000 DKK)
| Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
72
|
293
|
382 |
| Earnings before taxes |
-9,792
|
-9,909
|
-27,847 |
| EBITDA |
-9,549
|
-9,543
|
-27,555 |
| Total assets |
4,082
|
11,264
|
22,076 |
| Current assets |
3,558
|
10,475
|
21,002 |
| Current liabilities |
2,974
|
1,507
|
6,702 |
| Equity capital |
1,108
|
9,758
|
15,374 |
| - share capital |
3,802
|
3,782
|
3,407 |
| Employees (average) |
5
|
5
|
6 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Solvency |
27.1%
|
86.6%
|
69.6% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-238.1%
|
-85.4%
|
-124.4% |
| Current ratio |
119.6%
|
695.1%
|
313.4% |
| Return on equity (ROE) |
-883.8%
|
-101.5%
|
-181.1% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
-1
|
-1 |
| Chg. No. of employees % |
0%
|
-17%
|
-14% |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.